The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests

• Published in: Thrombosis and haemostasis Vol. 102; no. 4; p. 719
• Main Authors: Elsenberg, Ellen H A M, van Werkum, Jochem W, van de Wal, Ruud M A, Zomer, A Carla, Bouman, Heleen J, Verheugt, Freek W A, Berg, Jurriën M ten, Hackeng, Christian M
• Format: Journal Article
• Language: English
• Published: Germany 01.10.2009
• Subjects: Adenosine Diphosphate - metabolism; Angioplasty, Balloon, Coronary - adverse effects; Aspirin - therapeutic use; Biomarkers - metabolism; Blood Platelets - drug effects; Blood Platelets - immunology; Blood Platelets - metabolism; Blood Platelets - pathology; Cells, Cultured; Drug Combinations; Female; Humans; Interleukin-6 - genetics; Interleukin-6 - immunology; Interleukin-6 - metabolism; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests; Sensitivity and Specificity; Thrombosis - diagnosis; Thrombosis - etiology; Thrombosis - prevention & control; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use

High on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) are independently associated with an increased risk of atherothrombotic events. However, despite this positive correlation, the definitions of both HCPR and HAPR vary largely throughout studies and between...